RX-5902 exhibits direct and immunomodulatory anti-tumor activities in melanoma PDX models Apr 2, 2019
Unusual mechanism of resistance to the novel cytidine analog fluorocyclopentenylcytosine (RX-3117) Apr 1, 2019
The anticancer effects of RX-5902 result from inhibition of phosphorylated p68-mediated β-catenin nuclear translocation Apr 1, 2019
Results of a Phase 2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination with Everolimus in Subjects with Metastatic Renal Cell Carcinoma (mRCC) Feb 16, 2019
Activity of RX-3117, an Oral Antimetabolite Nucleoside, in Subjects with Advanced Urothelial Cancer: Preliminary Results from a Phase IIa Study Feb 15, 2019
Phase 1/2 Study Of Rx-3117, An Oral Antimetabolite Nucleoside, In Combination With Nab-Paclitaxel (Nab-Pac) As First Line Treatment of Metastatic Pancreatic Cancer (Met-Pc):Preliminary Results Jan 18, 2019
RX-3117, A Novel, Oral Nucleoside Analog, in Combination with Nab-paclitaxel (NAB-PAC) in First-line Metastatic Pancreatic Cancer (MET-PC): Safety, Tolerability, and Preliminary Responses Oct 2, 2018
Preliminary Results From an Ongoing Phase 2a Study of RX-3117, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC) Jun 1, 2018
Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68), Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC) Jun 1, 2018
